Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea’s Celltrion Initiates Clinical Trials Of Roche’s Rituxan Biosimilar

This article was originally published in The Pink Sheet Daily

Executive Summary

Celltrion takes a step forward in its biosimilar ambitions by commencing clinical trials of a key pipeline product.

You may also be interested in...

Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth

SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year

Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News

Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.

Korea's Celltrion Posts Record-High Q1 Sales And Net Profit, Riding On Biosimilar Prospects

SEOUL - South Korea's biosimilar front-runner Celltrion Inc. continued its upward swing in the first quarter of 2011with first quarter sales and net profit reaching record highs


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts